+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare-associated Infectious Disease Diagnostics Market by Test Method (Immunoassays, Microbiology, Molecular Diagnostics), Pathogen Type (Bacterial, Fungal, Parasitic), End User, Sample Type - Global Forecast 2025-2030- Product Image
Healthcare-associated Infectious Disease Diagnostics Market by Test Method (Immunoassays, Microbiology, Molecular Diagnostics), Pathogen Type (Bacterial, Fungal, Parasitic), End User, Sample Type - Global Forecast 2025-2030- Product Image
Sale

Healthcare-associated Infectious Disease Diagnostics Market by Test Method (Immunoassays, Microbiology, Molecular Diagnostics), Pathogen Type (Bacterial, Fungal, Parasitic), End User, Sample Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5181418
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The healthcare-associated infectious disease diagnostics market is advancing as medical providers worldwide seek precise, efficient, and scalable solutions for infection control and clinical decision making. As the landscape shifts towards innovation and integration, senior executives must have a clear strategic overview of opportunities and actionable insights guiding investments and operations.

Market Snapshot: Healthcare-Associated Infectious Disease Diagnostics Market Growth

The Healthcare-associated Infectious Disease Diagnostics Market grew from USD 4.37 billion in 2024 to USD 4.76 billion in 2025. It is expected to continue expanding at a CAGR of 8.39%, reaching USD 7.10 billion by 2030. This trajectory reflects heightened adoption of rapid diagnostics, continued transition from classic culture to molecular and immunoassay technologies, and increased operational focus from healthcare networks across major global regions.

Scope & Segmentation of the Market

This report provides an executive assessment of the sector’s main segments, stakeholder priorities, and technology trends. Market segmentation spans methodologies, pathogen classes, end users, sample types, regions, and top industry players.

  • Test Methodologies: Immunoassays (including chemiluminescent immunoassay, ELISA, lateral flow assays), microbiology (aerobic culture, anaerobic culture, microscopy, sensitivity testing), and molecular diagnostics (isothermal amplification, PCR, sequencing).
  • Pathogen Types: Bacterial (such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus), fungal (Aspergillus species, Candida species, Cryptococcus neoformans), parasitic (malaria parasites, Toxoplasma gondii), and viral (coronavirus, influenza virus, norovirus, respiratory syncytial virus) targets.
  • End Users: Diagnostic laboratories, independent and reference labs, hospital-based clinical pathology and microbiology units, point of care in clinics, emergency departments, and long-term care facilities.
  • Sample Types: Blood (serum, whole blood), cerebrospinal fluid, respiratory (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (deep tissue, surface samples).
  • Regions & Countries: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (such as United Kingdom, Germany, France, Russia, UAE, Saudi Arabia, South Africa), and Asia-Pacific (China, India, Japan, Australia, South Korea, among others).
  • Leading Industry Players: Roche Diagnostics International AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., Bio-Rad Laboratories, Inc., and DiaSorin S.p.A.

Key Takeaways for Decision Makers

  • Technological transformation is ongoing, with high-throughput analyzers and molecular diagnostics increasingly deployed across centralized labs and at the point of care.
  • Emerging platforms leverage automation and digital integration, allowing infection surveillance and clinical workflow optimization directly from diagnostic data inputs.
  • Product innovation is driven by a shift towards multiplex panel assays, enabling detection of multiple pathogens from a single patient specimen.
  • Regional manufacturing hubs and dual-sourcing strategies are being prioritized to strengthen supply chain security and support localized regulatory submissions.
  • Collaboration with academic and research partners accelerates assay validation, expands sequencing-based workflows, and supports antimicrobial resistance profiling efforts.
  • User demand for actionable, bedside diagnostics is supporting market growth, particularly in rapidly developing regions and in response to complex or emerging infectious disease threats.

Tariff Impact on Diagnostics Supply Chains and Market Dynamics (2025)

Revised United States tariffs affecting diagnostic reagents and instruments have prompted manufacturers to adapt supply chains by considering alternative sourcing and distribution. Laboratories are shifting protocols to maximize reagent efficiency, while providers work with global partners to qualify new raw materials and adjust manufacturing processes. These changes foster a more robust and transparent procurement environment and are encouraging vertical integration of diagnostic solutions across the market.

Methodology & Data Sources

The report is grounded in primary interviews with infectious disease experts, laboratory managers, and procurement professionals, complemented by comprehensive secondary research across peer-reviewed publications, regulatory filings, and industry briefings. An expert panel reviewed findings, and stakeholder workshops provided validation, ensuring conclusions reflect real-world perspectives and market realities.

Why This Report Matters

  • Informs strategic planning by mapping critical technology advances and competitive positioning in infectious disease diagnostics.
  • Enables executives to anticipate regulatory shifts, changing procurement priorities, and emerging partnership opportunities in high-impact segments.
  • Supplies actionable intelligence for investment, new product launches, and operational transformation across global healthcare networks.

Conclusion

This report delivers a strategic foundation for leadership teams navigating innovation and complexity in healthcare-associated infectious disease diagnostics. By leveraging these insights, organizations can confidently advance growth, resilience, and patient impact in a rapidly evolving sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of rapid molecular diagnostic assays for multidrug-resistant organism identification in hospital settings
5.2. Implementation of AI-driven algorithms for early detection of surgical site infections in postoperative patients
5.3. Expansion of point-of-care CRISPR-based assays for rapid identification of hospital-acquired pathogens in outpatient settings
5.4. Adoption of multiplex PCR panels for simultaneous detection of bacterial and viral healthcare-associated infections in critical care units
5.5. Integration of real-time antimicrobial susceptibility testing platforms to optimize antibiotic stewardship in intensive care
5.6. Development of high-throughput whole genome sequencing workflows to track nosocomial infection outbreaks in real time
5.7. Implementation of teleinfectious disease consultation services to reduce diagnosis delays in remote healthcare facilities
5.8. Emergence of nanotechnology-enhanced biosensors for continuous monitoring of bloodstream infections in hospitalized patients
5.9. Deployment of cloud-based surveillance dashboards for cross-hospital tracking of multidrug-resistant organism transmission patterns
5.10. Cost-benefit analysis of automated microbiology laboratories leveraging robotics to accelerate pathogen identification and reporting
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method
8.1. Introduction
8.2. Immunoassays
8.2.1. Chemiluminescent Immunoassay
8.2.2. ELISA
8.2.3. Lateral Flow Assays
8.3. Microbiology
8.3.1. Culture
8.3.1.1. Aerobic Culture
8.3.1.2. Anaerobic Culture
8.3.2. Microscopy
8.3.3. Sensitivity Testing
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. PCR
8.4.3. Sequencing
9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type
9.1. Introduction
9.2. Bacterial
9.2.1. Clostridium Difficile
9.2.2. Escherichia Coli
9.2.3. Pseudomonas Aeruginosa
9.2.4. Staphylococcus Aureus
9.3. Fungal
9.3.1. Aspergillus Species
9.3.2. Candida Species
9.3.3. Cryptococcus Neoformans
9.4. Parasitic
9.4.1. Malaria Parasites
9.4.2. Toxoplasma Gondii
9.5. Viral
9.5.1. Coronavirus
9.5.2. Influenza Virus
9.5.3. Norovirus
9.5.4. Respiratory Syncytial Virus
10. Healthcare-associated Infectious Disease Diagnostics Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Independent Laboratories
10.2.2. Reference Laboratories
10.3. Hospitals
10.3.1. Clinical Pathology Laboratories
10.3.2. Microbiology Laboratories
10.4. Point Of Care
10.4.1. Clinics
10.4.2. Emergency Departments
10.4.3. Long Term Care Facilities
11. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type
11.1. Introduction
11.2. Blood
11.2.1. Serum
11.2.2. Whole Blood
11.3. Cerebrospinal Fluid
11.4. Respiratory
11.4.1. Bronchoalveolar Lavage
11.4.2. Nasopharyngeal Swabs
11.4.3. Sputum
11.5. Urine
11.5.1. Catheterized Urine
11.5.2. Midstream Urine
11.6. Wound Swabs
11.6.1. Deep Tissue Samples
11.6.2. Surface Swabs
12. Americas Healthcare-associated Infectious Disease Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Diagnostics International AG
15.3.2. Abbott Laboratories
15.3.3. Danaher Corporation
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. Siemens Healthineers AG
15.3.6. Becton, Dickinson and Company
15.3.7. bioMérieux SA
15.3.8. QIAGEN N.V.
15.3.9. Bio-Rad Laboratories, Inc.
15.3.10. DiaSorin S.p.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCHAI
FIGURE 24. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCHCONTACTS
FIGURE 26. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 237. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
TABLE 238. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2030 (USD MILLION)
TABLE 239. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
TABLE 240. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
TABLE 241. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
TABLE 242. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2030 (USD MILLION)
TABLE 243. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
TABLE 244. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2030 (USD MILLION)
TABLE 245. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 246. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 247. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 248. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 249. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
TABLE 250. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
TABLE 251. CANADA HEALT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Healthcare-associated Infectious Disease Diagnostics market report include:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • bioMérieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.1 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents & Kits, Software & Services), Technology (Immunoassays, Microbiology Culture, Molecular Diagnostics), Pathogen, Application, End User - Global Forecast 2025-2030 - Product Image

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents & Kits, Software & Services), Technology (Immunoassays, Microbiology Culture, Molecular Diagnostics), Pathogen, Application, End User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Enteric Disease Testing Market by Test Method (Biochemical Tests, Culture Methods, Immunoassays), Product Type (Consumables, Instruments, Software & Services), End User, Pathogen, Sample Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Enteric Disease Testing Market by Test Method (Biochemical Tests, Culture Methods, Immunoassays), Product Type (Consumables, Instruments, Software & Services), End User, Pathogen, Sample Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Gastrointestinal Pathogen Testing Market Report 2025 - Product Image

Gastrointestinal Pathogen Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Food Pathogen Detection Technology Market Report 2025 - Product Image

Food Pathogen Detection Technology Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Respiratory Pathogen Testing Kits Market Report and Forecast 2025-2034 - Product Image

Respiratory Pathogen Testing Kits Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From

About the Hospital Acquired Infection Diagnostics Market

The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics. The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection. Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.